st2825 and Lymphoma

st2825 has been researched along with Lymphoma* in 2 studies

Reviews

1 review(s) available for st2825 and Lymphoma

ArticleYear
Targeting the Toll-like receptor/interleukin 1 receptor pathway in human diseases: rational design of MyD88 inhibitors.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:2

    Toll-like receptor (TLR)/interleukin (IL) 1 receptor (IL-1R) play a fundamental role in the immune response. These receptors are distributed in various cellular compartments and recognize different components of pathogens. All TLR/IL-1Rs, with the exception of TLR3, interact with MyD88, an intracellular adapter protein that triggers a signaling cascade that culminates in the expression of inflammatory genes. Because aberrant activation of TLR/IL-1Rs can promote the onset of inflammatory or autoimmune diseases and malignancies, this pathway has attracted considerable interest as a potential therapeutic target. Given the central role of MyD88 in TLR/IL-1R signaling, we set out different strategies to develop drugs that can block its function. Structural and functional analysis of the MyD88 domains allowed us to identify crucial residues required for MyD88 homodimerization. Moreover, we developed small cell-permeable peptides and peptidomimetic agents that inhibit MyD88 homodimerization and function. Our results pave the way for the development of new therapeutic drugs for the inhibition of MyD88-dependent signaling.

    Topics: Drug Design; Heterocyclic Compounds, 2-Ring; Humans; Lymphoma; Myeloid Differentiation Factor 88; Peptides; Receptors, Interleukin-1; Signal Transduction; Spiro Compounds; Toll-Like Receptors; Waldenstrom Macroglobulinemia

2013

Other Studies

1 other study(ies) available for st2825 and Lymphoma

ArticleYear
MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells.
    Anticancer research, 2017, Volume: 37, Issue:11

    Myeloid differentiation primary response gene 88 (MYD88), which activates the nuclear factor kappa B (NF-κB) pathway, is important for the growth of lymphoma and leukaemia cells. In this study, we investigated the effects of ST2825, a synthetic peptidomimetic compound which inhibits MYD88 homodimerization, on their growth.. Seven lymphoma and leukaemia cell lines including TMD8, a B-cell lymphoma line with MYD88-activating mutation, were treated with ST2825 and analysed for cell proliferation and expression of NF-κB signalling-related molecules.. ST2825 suppressed the growth of all cell lines by inducing apoptosis and down-regulating phosphorylation of NF-κB pathway components inhibitor of nuclear factor kappa B kinase (IκB) and reticuloendotheliosis oncogene A (RelA), as well as of MYD88 activator Bruton tyrosine kinase (BTK), suggesting that MYD88 may affect BTK activity. ST2825 effects were specific as MYD88-targeting siRNA also suppressed phosphorylation of NF-κB signalling proteins and BTK in TMD8 cells.. ST2825 may be a novel drug targeting not only B-lymphoid malignancies with MYD88 mutations, but also lymphoma and leukaemia with wild-type MYD88.

    Topics: Apoptosis; Cell Proliferation; Heterocyclic Compounds, 2-Ring; Humans; Leukemia; Lymphoma; Myeloid Differentiation Factor 88; Spiro Compounds; Tumor Cells, Cultured

2017